ATE330630T1 - Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose - Google Patents

Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose

Info

Publication number
ATE330630T1
ATE330630T1 AT97903837T AT97903837T ATE330630T1 AT E330630 T1 ATE330630 T1 AT E330630T1 AT 97903837 T AT97903837 T AT 97903837T AT 97903837 T AT97903837 T AT 97903837T AT E330630 T1 ATE330630 T1 AT E330630T1
Authority
AT
Austria
Prior art keywords
anticoagulant
thrombosis
treatment
antibodies against
humanized antibodies
Prior art date
Application number
AT97903837T
Other languages
English (en)
Inventor
Michael Neal Blackburn
William Robert Church
Giora Zeev Feuerstein
Mitchell Stuart Gross
Andrew John Nichols
Eduardo Agustin Padlan
Arunbhai Haribhai Patel
Daniel Robert Sylvester
Original Assignee
Smithkline Beecham Corp
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Univ Vermont filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE330630T1 publication Critical patent/ATE330630T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97903837T 1996-01-17 1997-01-17 Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose ATE330630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
ATE330630T1 true ATE330630T1 (de) 2006-07-15

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97903837T ATE330630T1 (de) 1996-01-17 1997-01-17 Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose

Country Status (25)

Country Link
US (5) US6005091A (de)
EP (2) EP1832297A1 (de)
JP (2) JP2000503210A (de)
KR (1) KR100553629B1 (de)
CN (1) CN1213312A (de)
AR (1) AR005658A1 (de)
AT (1) ATE330630T1 (de)
AU (1) AU706397B2 (de)
BR (1) BR9707049A (de)
CZ (1) CZ299452B6 (de)
DE (1) DE69736197T2 (de)
DK (1) DK1007089T3 (de)
ES (1) ES2267131T3 (de)
HU (1) HU225903B1 (de)
ID (1) ID17156A (de)
IL (1) IL125380A0 (de)
MA (1) MA24512A1 (de)
MX (1) MX9805810A (de)
NO (1) NO983284L (de)
NZ (2) NZ331014A (de)
PL (1) PL187274B1 (de)
PT (1) PT1007089E (de)
SI (1) SI1007089T1 (de)
TR (1) TR199801390T2 (de)
WO (1) WO1997026010A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2294833A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
DK1095143T3 (da) * 1998-05-08 2009-01-05 Sanquin Bloedvoorziening Inhibitor til diagnosticering og behandling af patienter med hæmofili A
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
ATE217889T1 (de) * 1998-08-28 2002-06-15 Genentech Inc Humane antikörper gegen faktor ix/ixa
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1127148B1 (de) * 1998-10-31 2012-08-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Varianten des humanisierten monoklonalen anti-krebs antikörpers cc49
WO2005016455A2 (en) 2003-08-14 2005-02-24 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
EP1194528B1 (de) * 1999-07-14 2007-03-07 D. Collen Research Foundation vzw Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
CA2425208C (en) * 2000-09-26 2013-04-09 Duke University Rna aptamers and methods for identifying the same
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2418808A1 (en) * 2001-06-12 2002-12-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor viii antibody
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2003248744C1 (en) 2002-06-28 2009-12-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035754A1 (ja) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
IN2014DN10515A (de) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CN101842388B (zh) 2007-09-13 2013-09-04 德勒尼克斯治疗股份公司 针对β淀粉样肽的人源化抗体
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
US8187591B2 (en) * 2007-10-11 2012-05-29 The Regents Of The University Of California Methods of treating coagulopathy
US20110159006A1 (en) * 2008-06-19 2011-06-30 Erik Hack Use of anti-factor xi antibodies for prevention of thrombus formation
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
EA031025B1 (ru) 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
US10442868B2 (en) 2013-03-14 2019-10-15 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis B virus infections by administering receptor associated protein (RAP)
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
PT3177642T (pt) 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
KR102794955B1 (ko) * 2015-07-21 2025-04-15 다케다 파머수티컬 컴패니 리미티드 Xiia 인자의 단일클론 항체 저해제
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
BR112018014810A2 (pt) * 2016-01-22 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN116425879A (zh) 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
AU2017303205B2 (en) 2016-07-29 2024-08-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
IL265144B2 (en) 2016-09-06 2024-10-01 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
JP7227146B2 (ja) * 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
KR102702288B1 (ko) * 2016-12-23 2024-09-05 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TW202423960A (zh) 2017-09-29 2024-06-16 日商中外製藥股份有限公司 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
ES2901683T3 (es) 2018-12-21 2022-03-23 Kymab Ltd Anticuerpo biespecífico FIXAXFX con cadena ligera común
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
ES2152953T3 (es) * 1992-08-27 2001-02-16 Sanquin Bloedvoorziening Anticuerpos especificos para una proteina hemostatica, su utilizacion para aislar proteinas intactas, compuestos hemostaticos carentes de productos de segmentacion proteolitica de la proteina.
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
HK1029513A1 (en) 2001-04-06
EP1007089B1 (de) 2006-06-21
NZ331014A (en) 2000-01-28
DE69736197T2 (de) 2007-06-21
CN1213312A (zh) 1999-04-07
PT1007089E (pt) 2006-11-30
CZ299452B6 (cs) 2008-07-30
AR005658A1 (es) 1999-07-14
DE69736197D1 (de) 2006-08-03
AU706397B2 (en) 1999-06-17
PL327929A1 (en) 1999-01-04
DK1007089T3 (da) 2006-10-09
NZ501215A (en) 2001-04-27
SI1007089T1 (sl) 2006-12-31
NO983284L (no) 1998-09-16
KR100553629B1 (ko) 2006-10-04
HU225903B1 (en) 2007-12-28
US20020146411A1 (en) 2002-10-10
CZ222598A3 (cs) 2000-01-12
ES2267131T3 (es) 2007-03-01
HUP9900396A2 (hu) 1999-05-28
US20070003553A1 (en) 2007-01-04
US6391299B1 (en) 2002-05-21
EP1007089A4 (de) 2003-04-16
AU1830897A (en) 1997-08-11
JP2000503210A (ja) 2000-03-21
US6005091A (en) 1999-12-21
HUP9900396A3 (en) 2001-10-29
BR9707049A (pt) 2000-10-24
MX9805810A (es) 1998-11-30
IL125380A0 (en) 1999-03-12
PL187274B1 (pl) 2004-06-30
ID17156A (id) 1997-12-04
NO983284D0 (no) 1998-07-16
EP1832297A1 (de) 2007-09-12
US20070224198A1 (en) 2007-09-27
JP2007325602A (ja) 2007-12-20
EP1007089A1 (de) 2000-06-14
TR199801390T2 (xx) 1998-12-21
KR19990077329A (ko) 1999-10-25
MA24512A1 (fr) 1998-12-31
WO1997026010A1 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE384528T1 (de) Verwendung von einem faktor a inhibierenden oligosacchariden mit einem blutgerinnungshemmenden mittel zur behandlung von arterienthrombosen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69711011D1 (de) Zementzusatz, dessen Herstellungsverfahren und dessen Verwendung
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69515352D1 (de) Integriertes Verfahren zur Produktion von Mitteldistillaten
DE69635023D1 (de) Ulmwh (ultra-low-molecular weight heparin) zur behandlung von asthma
DE69114869D1 (de) Verfahren zur Bestimmung des Profils von Reifen.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
EP0758894A4 (de) Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69725580D1 (de) Prozess zur herstellung von aza zyclohexapeptide
FI964227A7 (fi) Hepariinia sitova proteiini verenmyrkytyksen hoitoon ja menetelmät sen valmistamiseksi
DE59106800D1 (de) Verfahren zur Herstellung von Benzylketonen.
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007089

Country of ref document: EP

REN Ceased due to non-payment of the annual fee